Study summary
Adjusting treatment based on tumor DNA in the blood improved outcomes
89.1%failure-free at 3 years with ctDNA-guided treatment
What was tested
Treatment intensified or eased according to how quickly Epstein-Barr virus DNA from the tumor cleared from the blood during induction chemotherapy, against a comparison group treated the standard way.
What they found
- 3-year failure-free survival was 89.1% with ctDNA-guided treatment.
- Risk of failure was 59% lower than in the comparison group (hazard ratio 0.41).
What it means
Nasopharyngeal carcinoma is a model for blood-test-guided cancer treatment because its tumor DNA carries the Epstein-Barr virus.
Last reviewed 2026-11-15 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.